Overview of the drug development pipeline for rhabdomyosarcoma
It has been observed that rhabdomyosarcoma is a rare soft-tissue cancer, which mainly affects people aged under 18 years. Though it accounts for more than 40% of all the soft-tissue cancers, it contributes to less than 3% of all the pediatric cancer indications. The incidence of rhabdomyosarcoma at a global level is about 4.5 cases per 1 million children. It has been found that the incidence of rhabdomyosarcoma in females is twice in Caucasians than that of African-Americans. With the unavailability of FDA-approved treatment for rhabdomyosarcoma, monotherapy is emerging as the most efficient approach for the treatment of rhabdomyosarcoma.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for rhabdomyosarcoma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Drug development for rhabdomyosarcoma market report: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of rhabdomyosarcoma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- Bayer
- BioInvent International
- bioMARCK Pharmaceuticals
Therapeutic assessment of the drug development pipeline for rhabdomyosarcoma by route of administration
- Intravenous
- Oral
- Inhalation
- Undisclosed
The intravenous (ROA) involves the administration of the drug directly through veins and in the oral technique, the molecules are delivered through the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for rhabdomyosarcoma by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for rhabdomyosarcoma are being developed as monotherapy drugs and many of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for rhabdomyosarcoma?
- What are the companies that are currently involved in the development of drug molecules for rhabdomyosarcoma?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX